References

Anttila, S., Huuhka., K. and Huuhka, M. et al. (2007) Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy. Pharmacogenomics Journal. 8 (2), 113-116.

References

Arranz , M., Collier, D. and Munro, J et al. (1996). Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neuroscience Letters, 217 (2-3), 177-178.

Arranz, M. Collier, D, Sodhi, M. et al. (1995). Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet, 346 (8970), 281-282.

References

Arranz, M., Munro,J., and Birkett, J., et al. (2000). Pharmacogenetic prediction of clozapine response. Lancet, 355, 1615-1616.

Arranz, M., Munro, J., and Sham, P. et al. (1998). Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophrenia Research, 32, 93-99.

References

Arias, B., Catalan, R., and Gasto, C. et al. (2005). Evidence for a combined genetic effect of the 5-HT1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. Journal of Psychopharmacology, 19 (2), 166-172.

References

Berrettini, W. H., Wileyto, E.P. and Epstein,L et al. COMT gene variants predict response to bupropion therapy for tobacco dependence. Biological Psychiatry, 61 (1), 111-118.

Bishop, J., Moline, J., Ellingrod, V., and Schultz, S. (2006). Serotonin 2A -1438 G/A and G protein Beta 3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology, 31 (10), 2281-2288.

References

Bruss, M, Kostanian, A. and Bonisch, H et al. (2005). The naturally occurring Arg219Leu variant of the human 5-HT1A receptor impairment of signal transduction. Pharmacogenetics, 15 (4), 257-264.

References

Choi, M., Yang, W., and Grimsby, J., et al. ((2005) . Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology, 52 (3), 155-162.

Cusin, C., Serretti, A. and Zanardi, R., et al. (2002). Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. International Journal of Neuropsychopharmacology, 5 (1), 27-35.

References

Dauvilliers, Y., Neidhart, E and Billiard, M et al. (2002).Sexual dimorphism of the COMT gene in narcolepsy is associated with response to modafinil. Pharmacogenomics Journal, 2(1), 65-68.

References

Deluca, V., Muller, D., and Hwang, R., et al. (2007). HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. Human Psychopharmacology, 22(7), 463-467.

References

Ellingrod, V., Lund, B and Miller, D. et. Al. (2003). 5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzepine in schizophrenia, Psychopharmacology Bulletin, 37(2), 109-112.

References

Gunes, A., Dahl, M., and Spina, E., et al;. (2008). Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Psychopharmacology, 190 (4), 479-484.

Gunes, A., Scordo, M and Jaanson, P. et al. (2007). Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology, 190 (4), 479-484.

References

Hamarman, S., Fossella,J., andUlger, C. et al. (2004). Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study. Journal of Child and Adolescent Psychopharmacology, 14 (4), 564-574.

Hamdani, N., Bonniere, M., and Ades, J., et al. (2005). Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics. Neuroscience Letters, 377 (1), 69-74.

References

Illi, A., Kampmanc, O., and Anttilac, S. et al. (2003). Interaction between angiotensin-converting enzyme and COMT genotypes in schizophrenics with poor response to conventional neuroleptics. European Neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 13 (3), 147-151.

Joober, R., Grizenko, N. and Sengupta, S. et al. (2007). Dopamine transporter 3’-UTR VNTR genotype and ADHD; a pharmaco-behavioural genetic study with methylphenidate. Neuropsychopharmacology 32 (6), 1370-1376.

References

Kereszturi, E., Tarnok, Z., and Bognar, E et al. (2008). COMT Val158Met polymorphism is associated with methylphenidate response in ADHD children. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147B (8), 1107-1113.

References

Kim, H., Lim, S. and Kim, S., et al. (2006). Monoamine gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA, 296 (13), 1609-1618.

Kirley, A., Lowe, N., and Hawi, Z et al. (2003). Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics, 121 (1), 50-54.

References

Kirchheiner, J., Nickchen, K., and Sasse, J. (2007). A 40- bp VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics Journal, 7 (1), 48-55.

Kishida, L., Kawanishi, C. and Furuno, T., et al. (2004). Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D2 receptor gene. Molecular Psychiatry, 9 (3), 293-298.

References

Lane, H., Lee, C, and Chang, Y., et al. (2004). Effects of dopamine D2 receptor Ser 311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. International Journal of Neuropschopharmacology, 7 (4) 461-470.

Lemonde, S., Du, L., and Bakish, D., et al. (2004). Association of the C (-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. International Journal of Neuropsychopharmacology, 7 (4), 381-385.

References

Lerman, C., Jepson, C., and Wileyto, E., et al (2006). Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology, 31 (1), 231-242.

References

Masoliver, E., Menoyo, A. and Perez, V. et al. (2006). Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder. Psychiatric Genetics, 16 (1), 25-29.

References

McGough,J., McCracken, J., and Swanson, J. et al. (2006). Pharmacogenetics and methylphenidate response in preschoolers with ADHD. [comment]. JAACAP, 45 (11), 1314-1322.

References

Meary, A., Brousse, G., Jamain, S., et al. (2008). Pharmacogenetic study of atypical antipsychotic drug response: involvement of the norepinephrine transporter gene. American Journal of Medical Genetics, Part B, Neuropsychiatric Genetics: the Official Publication of the International Society of Psychiatric Genetics. 147B (4), 491-494.

References

Mihara, K., Kondo, T., and Suzuki, A. et al. (2003). Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. American Journal of Medical Genetics Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics, 117B (1), 57-60.

Miller, D., Ellingrod, V., and Holman, T. et al (2005). Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. American Journal of Medical Genetics Part B, Neuropsychiatric Genetics, 133 (1), 97-100.

Muldar

References

.

Mrazek, David A. Psychiatric Pharmacogenomics New York, Oxford University Press, 2010.

References

Muldar,H., Franke, B., and van der-Beek van der A. et al. (2007a). The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics Journal, 7 (5), 318-324.

References

Rakvag, T., Klepstad, P., and Baar, C. et al (2005). The Val158Met polymorphism of the human COMT gene may influence morphine requirements in cancer pain patients. Pain, 116 (1-2), 73-78.

Reynolds, G., Zhang, Z and Zhang, X (2002). Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet, 3599 (9323), 2086-2087.

References

Rousseva, A., Henry, C. and van der Bulke, D. et al. (2003). Antidepressant induced mania, rapid cycling and the serotonin transporter gene polymorphism. ThePharmacogenomics Journal, 3 (2), 101-104.

References

Seeger, G., Schloss, P. and Schmidt, M (2001). Marker gene polymorphisms in hyperkinetic disorder- predictors of clinical response to treatment with methylphenidate? Neuroscience Letters 313 (1-2), 45-48.

Seretti, A., Artioli, P. and Lorenzo, C. (2004). The C(-1019)G polymorphism of the 5-HT1a gene promoter and antidepressant response in mood disorders: preliminary findings. International Journal of Neuropsychopharmacology, 7 (4), 453-460.

References

Stamm, T., Adli, M., and Kirchheiner, J. et al. (2008). Serotonin transporter gene and response to lithium augmentation in depression. Psychiatric Genetics, 18 (2), 92-97.

References

Stein, M., Waldman, I. and Sarampote, C et al. (2005). Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology, 30 (7), 1374-1382.

Stice, E., Spoor, S., and Bohon, C. et al. (2008). Relation between obesity and blunted striatal response to ood is moderated by Taq1A A1 allele. Science, 322 (5900), 449-452.

References

Templeman, L., Reynolds, G. and Arranz, B. et al. (2005). Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics and Genomics, 15 (4), 195-200.

Yu, Y., Tsai, S. and Liou, Y. (2006). Association study of two serotonin 1 A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. European Neuropsychopharmacology, 167 (7), 498-503.